Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab

被引：2

作者：

Bowens, Brendan K. ^{[1
]}

Chou, Eva ^{[2
]}

LaChance, David P. ^{[1
,3
]}

Huynh, James R. ^{[1
]}

Voorhees, Patrick ^{[4
]}

Do, Thanh C. ^{[3
]}

Shakir, Mohamed K. M. ^{[3
,5
]}

Hoang, Thanh D. ^{[3
,5
,6
]}

机构：

[1] Dwight D Eisenhower Army Med Ctr, Dept Med, Augusta, GA USA

[2] Walter Reed Natl Mil Med Ctr, Dept Ophthalmol, Bethesda, MD USA

[3] Uniformed Serv Univ Hlth Sci, Dept Med, Div Endocrinol, Bethesda, MD USA

[4] Walter Reed Natl Mil Med Ctr, Dept Pathol, Bethesda, MD USA

[5] Walter Reed Natl Mil Med Ctr, Dept Med, Div Endocrinol, Bethesda, MD USA

[6] Walter Reed Natl Mil Med Ctr, Div Endocrinol, 8901 Wisconsin Ave, Bethesda, MD 20889 USA

来源：

CLINICAL CASE REPORTS | 2022年 / 10卷 / 11期

关键词：

Graves' disease; pretibial myxedema; teprotumumab; thyroid eye disease; OPHTHALMOPATHY;

D O I：

10.1002/ccr3.6621

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report a 51-year-old woman with thyroid eye disease and biopsy-proven pretibial myxedema that was subsequently treated with teprotumumab with improvement.

引用

页数：4

共 18 条

[1] Triad of exophthalmos, pretibial myxedema, and acropachy in a patient with Graves' disease [J].

Anderson, CK ;

Miller, OF .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 48 (06) :970-972

[2]

[Anonymous], FDA APPROVES 1 TREAT

[3] Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in Fibrocytes [J].

Chen, Hong ;

Mester, Tuende ;

Raychaudhuri, Nupur ;

Kauh, Courtney Y. ;

Gupta, Shivani ;

Smith, Terry J. ;

Douglas, Raymond S. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (09) :E1635-E1640

[4] Graves' disease [J].

Davies, Terry F. ;

Andersen, Stig ;

Latif, Rauf ;

Nagayama, Yuji ;

Barbesino, Giuseppe ;

Brito, Maria ;

Eckstein, Anja K. ;

Stagnaro-Green, Alex ;

Kahaly, George J. .

NATURE REVIEWS DISEASE PRIMERS, 2020, 6 (01)

[5]

Doshi DN, 2008, CLIN DERMATOL, V26, P283, DOI 10.1016/j.clindermatol.2007.10.020

[6] Teprotumumab for the Treatment of Active Thyroid Eye Disease [J].

Douglas, R. S. ;

Kahaly, G. J. ;

Patel, A. ;

Sile, S. ;

Thompson, E. H. Z. ;

Perdok, R. ;

Fleming, J. C. ;

Fowler, B. T. ;

Marcocci, C. ;

Marino, M. ;

Antonelli, A. ;

Dailey, R. ;

Harris, G. J. ;

Eckstein, A. ;

Schiffman, J. ;

Tang, R. ;

Nelson, C. ;

Salvi, M. ;

Wester, S. ;

Sherman, J. W. ;

Vescio, T. ;

Holt, R. J. ;

Smith, T. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (04) :341-352

[7] Pretibial myxedema - Pathophysiology and treatment options [J].

Fatourechi, V .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2005, 6 (05) :295-309

[8] 2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease [J].

Hoang, Thanh D. ;

Stocker, Derek J. ;

Chou, Eva L. ;

Burch, Henry B. .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2022, 51 (02) :287-304

[9]

Jimenez Amber, 2021, JAAD Case Rep, V10, P28, DOI 10.1016/j.jdcr.2021.01.033

[10] Glycosaminoglycans in thyroid eye disease [J].

Kahaly, G ;

Forster, G ;

Hansen, C .

THYROID, 1998, 8 (05) :429-432

← 1 2 →